Jamal et al. found that miR-125a-5p pretreatment synergistically increased the cytotoxic effects of erlotinib (first-generation EGFR-TKI inhibitors) and decreased the IC50 values of tumor cells, and miR-125a-5p significantly enhanced the apoptotic effects induced by erlotinib [13]. The gene discussed is EGFR; the disease is neoplasm.